Medicenna Therapeutics Corp.
MDNA.TO
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.02M | 5.14M | 5.53M | 5.84M | 4.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.63M | 13.48M | 13.48M | 13.85M | 12.60M |
| Operating Income | -13.63M | -13.48M | -13.48M | -13.85M | -12.60M |
| Income Before Tax | -19.73M | -19.68M | -19.40M | -18.88M | -11.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.73 | -19.68 | -19.40 | -18.88 | -11.42 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.73M | -19.68M | -19.40M | -18.88M | -11.42M |
| EBIT | -13.63M | -13.48M | -13.48M | -13.85M | -12.60M |
| EBITDA | -13.62M | -13.47M | -13.48M | -13.85M | -12.60M |
| EPS Basic | -0.27 | -0.28 | -0.28 | -0.27 | -0.16 |
| Normalized Basic EPS | -0.17 | -0.17 | -0.17 | -0.17 | -0.10 |
| EPS Diluted | -0.27 | -0.28 | -0.28 | -0.27 | -0.16 |
| Normalized Diluted EPS | -0.17 | -0.17 | -0.17 | -0.17 | -0.10 |
| Average Basic Shares Outstanding | 298.11M | 289.74M | 282.54M | 278.55M | 278.46M |
| Average Diluted Shares Outstanding | 298.11M | 289.74M | 282.54M | 278.55M | 278.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
